von Stintino » 27.03.2015, 10:56
Hallo Zufall,
ich musste an dich bzw. deinen Sohn denken, als ich den folgenden Artikel gelesen habe.
Hier wird eine Studie mit einer 30-köpfigen Patientengruppe beschrieben, deren Lebensqualität stark eingeschränkt, eine Therapie aber eigentlich noch nicht angeraten ist.
Es wird angenommen, dass eine erhöhte Zytokinproduktion die Ursache für z. B. starke Müdigkeit ist. "Ruxolitinib" bzw. der Kinasehemmer JAK-2 scheint in dieser sehr kleinen Kohorte eine Verbesserung der Lebensqualität mit sich zu bringen.
Vielleicht ist das Thema euch eine Frage wert beim nächsten Kontrolltermin?
Alles Gute!
Stintino
_____________________________________________
Hier der Artikel der CLL Global Research Foundation:
Increasing Quality of Life For CLL Patients
Chronic lymphocytic leukemia (CLL) has a profound effect on patients' quality of life because of a number of disease-related symptoms among which fatigue is perhaps the best recognized. Currently available symptomatic treatments are only partially effective. Therefore, for patients in whom CLL-related symptoms are uncontrollable, anti-leukemic therapy is often administered.
Realizing that most disease related symptoms are caused by hormone-like substances, termed cytokines, produced at high levels by CLL cells, Dr. Estrov, a Professor of Leukemia at MD Anderson Cancer Center and a CLL Global Alliance funded researcher, was looking for a drug that would efficiently reduce the levels of those cytokines.
Most CLL cells reside in the bone marrow and lymph nodes where local factors stimulate the proliferation and increase the life span of CLL cells. While investigating these mechanisms in his laboratory, Dr. Estrov and his team discovered that stimulation of CLL cells results in activation of a factor termed Janus kinase (JAK)-2 and the drug ruxolitinib (Jakafi) inhibits this effect. The JAK2 inhibitor ruxolitinib has been used successfully in myelofibrosis, a disease in which JAK2 is activated and induces the production of several cytokines, a significant number of which are produced by CLL cells.
To test whether ruxolitinib would alleviate the symptoms of patients with CLL that otherwise do not require anti-leukemia therapy, Dr. Estrov initiated a small clinical trial. With the support of Incyte Corporation, the drug's manufacturer, ruxolitinib has been administered to CLL patients. In the vast majority of the 30 patients that were enrolled onto the study thus far, ruxolitinib significantly reduced CLL-related symptoms and improved the patients' quality of life.
Hallo Zufall,
ich musste an dich bzw. deinen Sohn denken, als ich den folgenden Artikel gelesen habe.
Hier wird eine Studie mit einer 30-köpfigen Patientengruppe beschrieben, deren Lebensqualität stark eingeschränkt, eine Therapie aber eigentlich noch nicht angeraten ist.
Es wird angenommen, dass eine erhöhte Zytokinproduktion die Ursache für z. B. starke Müdigkeit ist. "Ruxolitinib" bzw. der Kinasehemmer JAK-2 scheint in dieser sehr kleinen Kohorte eine Verbesserung der Lebensqualität mit sich zu bringen.
Vielleicht ist das Thema euch eine Frage wert beim nächsten Kontrolltermin?
Alles Gute!
Stintino
_____________________________________________
Hier der Artikel der CLL Global Research Foundation:
Increasing Quality of Life For CLL Patients
Chronic lymphocytic leukemia (CLL) has a profound effect on patients' quality of life because of a number of disease-related symptoms among which fatigue is perhaps the best recognized. Currently available symptomatic treatments are only partially effective. Therefore, for patients in whom CLL-related symptoms are uncontrollable, anti-leukemic therapy is often administered.
Realizing that most disease related symptoms are caused by hormone-like substances, termed cytokines, produced at high levels by CLL cells, Dr. Estrov, a Professor of Leukemia at MD Anderson Cancer Center and a CLL Global Alliance funded researcher, was looking for a drug that would efficiently reduce the levels of those cytokines.
Most CLL cells reside in the bone marrow and lymph nodes where local factors stimulate the proliferation and increase the life span of CLL cells. While investigating these mechanisms in his laboratory, Dr. Estrov and his team discovered that stimulation of CLL cells results in activation of a factor termed Janus kinase (JAK)-2 and the drug ruxolitinib (Jakafi) inhibits this effect. The JAK2 inhibitor ruxolitinib has been used successfully in myelofibrosis, a disease in which JAK2 is activated and induces the production of several cytokines, a significant number of which are produced by CLL cells.
To test whether ruxolitinib would alleviate the symptoms of patients with CLL that otherwise do not require anti-leukemia therapy, Dr. Estrov initiated a small clinical trial. With the support of Incyte Corporation, the drug's manufacturer, ruxolitinib has been administered to CLL patients. In the vast majority of the 30 patients that were enrolled onto the study thus far, ruxolitinib significantly reduced CLL-related symptoms and improved the patients' quality of life.